Evaluating Heart Failure Treatment Adapted by Monitoring the sST2 Biomarker to Reduce Hospital Readmissions

What this Trial Is About

Heart failure remains a significant health concern due to high rates of rehospitalization, mortality, and related costs. Researchers are evaluating whether monitoring the biomarker soluble suppression of tumorigenicity 2 sST2 can help guide medical management in patients with acute heart failure to reduce hospital readmissions. This study is a multicenter, blinded, randomized controlled trial involving 710 patients followed over 24 months to assess the impact of sST2-guided therapy on health outcomes and costs. Participants are randomly assigned to one of two groups usual care where sST2 levels are not disclosed, or an intervention group where sST2 levels are monitored and used to guide therapy at hospital discharge and during follow-up visits at 6, 12, 18, and 24 months. The study compares the cost-utility ratio as the primary outcome, with secondary outcomes including cost-efficacy, hospitalizations for heart failure, and cardiac remodeling markers. Throughout the trial, patients undergo evaluations at 6, 12, 18, and 24 months to monitor health status and biomarker levels. Researchers measure quality-adjusted life years, hospitalization rates, and economic outcomes. Safety and treatment effects are assessed over the two-year follow-up period to determine the potential benefits of using sST2 biomarker-guided therapy in managing acute heart failure.

Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure